Becton Dickinson and Company (BDX) : The total money flow in Becton Dickinson and Company (BDX) was negative ($1.72 million), which signals selling by the traders on Wednesdays session. They trimmed their holdings by selling the stock on downticks to the tune of $4.45 million. In comparison, the inflow of money into the stock on upticks was $2.73 million. The uptick to downtick ratio was 0.61. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $2 million. The negative money flow of ($2 million) confirms the selling in Becton Dickinson and Company (BDX) on strength. Becton Dickinson and Company (BDX) gained $0.02 at $178.99, a gain of 0.01% over the previous days close. However, the stock registered -0.28% in the week.
Becton, Dickinson and Company has dropped 0.12% in the last five trading days, however, the shares have posted positive gains of 1.46% in the last 4 weeks. Becton, Dickinson and Company is up 6.94% in the last 3-month period. Year-to-Date the stock performance stands at 17.69%.
Becton Dickinson and Company (BDX) : The consensus on Becton Dickinson and Company (BDX) based on 13 analyst recommendation on the company stock is 1.62, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 9 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Becton Dickinson and Company (NYSE:BDX): The stock opened at $180.57 and touched an intraday high of $180.57 on Wednesday. During the day, the stock corrected to an intraday low of $178.24, however, the bulls stepped in and pushed the price higher to close in the green at $179.17 with a gain of 0.11% for the day. The total traded volume for the day was 592,686. The stock had closed at $178.97 in the previous trading session.
Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.